Cervical Cancer Test Market & Patients – Pap Smear, HPV DNA, VIA – Test & Patients – Worldwide 9438 Now Available at LifeScienceIndustryResearch.com

Cervical Cancer Test Market & Patients – Pap Smear, HPV DNA, VIA – Test & Patients – Worldwide

232 pages report Published in Apr 2014

Diagnostics

Publisher: Renub Research

Report Description
Table of Content
Related Reports

Renub Research report titled “”Cervical Cancer Test Market & Patients – Pap Smear, HPV DNA, VIA – Test & Patients – Worldwide” provides a comprehensive analysis of the current state of this market and likely future evolution over the next 5 years. This 232 page report with 240 Figures and 14 Table provides a complete analysis of top 20 Countries Cervical Cancer Test Market & Population. All the 20 countries in the report have been studied from 3 viewpoints.

Cervical cancer Test Population (2007-2020)

Pap smear test population (2007-2020)
HPV DNA test population (2007-2020)
VIA test Population (2007-2020)

Cervical Cancer Mortality Population (2001-2011)

Cervical Cancer Test Market (2007-2020)

Pap smear test market (2007-2020)
HPV DNA test market (2007-2020)
VIA test market (2007-2020)

All the 20 Countries studied in the report are as follows

United Kingdom
France
Germany
Italy
Spain
Sweden
Switzerland
Norway
Netherlands
United States
Canada
Japan
Korea
Singapore
Malaysia
Australia
India
China
Thailand
Indonesia

Table of Contents

1. Executive Summary

2. Worldwide Cervical Cancer Test (Screening) Population & Forecast

3. Worldwide Cervical Cancer Test (Screening) Market & Forecast
3.1 Worldwide Cervical Cancer Pap Smear Test (Screening) Market & Forecast
3.2 Worldwide Cervical Cancer HPV DNA Test (Screening) Market & Forecast
3.3 Worldwide - Cervical Cancer Visual Inspection with Acetic Acid (VIA) Test (Screening) Market & Forecast

4. Worldwide Cervical Cancer Test (Screening) Population Share, Market Share & Forecast
4.1 Worldwide Cervical Cancer Test (Screening) Population Share & Forecast
4.2 Worldwide Cervical Cancer Test (Screening) Market Share & Forecast
4.3 Worldwide Cervical Cancer Pap Smear Test (Screening) Market Share & Forecast
4.4 Worldwide Cervical Cancer HPV DNA Test (Screening) Market Share & Forecast
4.5 Worldwide Cervical Cancer VIA Test (Screening) Market Share & Forecast

5. United Kingdom – Cervical Cancer Test Analysis
5.1 United Kingdom Cervical Cancer Test (Screening) Population
5.1.1 United Kingdom Cervical Cancer Pap Smear Test Population & Forecast
5.1.2 United Kingdom Cervical Cancer HPV DNA Test Population & Forecast
5.2 United Kingdom Cervical Cancer Mortality
5.3 United Kingdom Cervical Cancer Test (Screening) Analysis
5.3.1 United Kingdom Cervical Cancer Test Market & Forecast
5.3.2 United Kingdom Pap Smear Test Market & Forecast
5.3.3 United Kingdom HPV DNA Test Market & Forecast

6. France – Cervical Cancer Test Analysis
6.1 France Cervical Cancer Test (Screening) Population
6.1.1 France Cervical Cancer Pap Smear Test Population & Forecast
6.1.2 France Cervical Cancer HPV DNA Test Population & Forecast
6.2 France Cervical Cancer Mortality
6.3 France Cervical Cancer Test (Screening) Analysis
6.3.1 France Cervical Cancer Test Market & Forecast
6.3.2 France Pap Smear Test Market & Forecast
6.3.3 France HPV DNA Test Market & Forecast

7. Germany – Cervical Cancer Test Analysis
7.1 Germany Cervical Cancer Test (Screening) Population
7.1.1 Germany Cervical Cancer Pap Smear Test Population & Forecast
7.1.2 Germany Cervical Cancer HPV DNA Test Population & Forecast
7.2 Germany Cervical Cancer Mortality
7.3 Germany Cervical Cancer Test (Screening) Market
7.3.1 Germany Cervical Cancer Test Market & Forecast
7.3.2 Germany Pap Smear Test Market & Forecast
7.3.3 Germany HPV DNA Test Market & Forecast

8. Italy – Cervical Cancer Test Analysis
8.1 Italy Cervical Cancer Test (Screening) Population
8.1.1 Italy Cervical Cancer Pap Smear Test Population & Forecast
8.1.2 Italy Cervical Cancer HPV DNA Test Population & Forecast
8.2 Italy Cervical Cancer Mortality
8.3 Italy Cervical Cancer Test (Screening) Market
8.3.1 Italy Cervical Cancer Test Market & Forecast
8.3.2 Italy Pap Smear Test Market & Forecast
8.3.3 Italy HPV DNA Test Market & Forecast

9. Spain – Cervical Cancer Test Analysis
9.1 Spain Cervical Cancer Test (Screening) Population
9.1.1 Spain Cervical Cancer Pap Smear Test Population & Forecast
9.1.2 Spain Cervical Cancer HPV DNA Test Population & Forecast
9.2 Spain Cervical Cancer Mortality
9.3 Spain Cervical Cancer Test (Screening) Market
9.3.1 Spain Cervical Cancer Test Market & Forecast
9.3.2 Spain Pap Smear Test Market & Forecast
9.3.3 Spain HPV DNA Test Market & Forecast

10. Sweden – Cervical Cancer Test Analysis
10.1 Sweden Cervical Cancer Test (Screening) Population
10.1.1 Sweden Cervical Cancer Pap Smear Test Population & Forecast
10.1.2 Sweden Cervical Cancer HPV DNA Test Population & Forecast
10.2 Sweden Cervical Cancer Mortality
10.3 Sweden Cervical Cancer Test (Screening) Market
10.3.1 Sweden Cervical Cancer Test Market & Forecast
10.3.2 Sweden Pap Smear Test Market & Forecast
10.3.3 Sweden HPV DNA Test Market & Forecast

11. Switzerland – Cervical Cancer Test Analysis
11.1 Switzerland Cervical Cancer Test (Screening) Population
11.1.1 Switzerland Cervical Cancer Pap Smear Test Population & Forecast
11.1.2 Switzerland Cervical Cancer HPV DNA Test Population & Forecast
11.2 Switzerland Cervical Cancer Mortality
11.3 Switzerland Cervical Cancer Test (Screening) Market
11.3.1 Switzerland Cervical Cancer Test Market & Forecast
11.3.2 Switzerland Pap smear Test Market & Forecast
11.3.3 Switzerland HPV DNA Test Market & Forecast

12. Norway – Cervical Cancer Test Analysis
12.1 Norway Cervical Cancer Test (Screening) Population
12.1.1 Norway Cervical Cancer Pap Smear Test Population & Forecast
12.1.2 Norway Cervical Cancer HPV DNA Test Population & Forecast
12.2 Norway Cervical Cancer Mortality
12.3 Norway Cervical Cancer Test (Screening) Market
12.3.1 Norway Cervical Cancer Test Market & Forecast
12.3.2 Norway Pap Smear Test Market & Forecast
12.3.3 Norway HPV DNA Test Market & Forecast

13. Netherlands – Cervical Cancer Test Analysis
13.1 Netherlands Cervical Cancer Test (Screening) Population
13.1.1 Netherlands Cervical Cancer Pap Smear Test Population & Forecast
13.1.2 Netherlands Cervical Cancer HPV DNA Test Population & Forecast
13.2 Netherlands Cervical Cancer Mortality
13.3 Netherlands Cervical Cancer Test (Screening) Market
13.3.1 Netherlands Cervical Cancer Test Market & Forecast
13.3.2 Netherlands Pap Smear Test Market & Forecast
13.3.3 Netherlands HPV DNA Test Market & Forecast

14. United States – Cervical Cancer Test Analysis
14.1 United States Cervical Cancer Test (Screening) Population
14.1.1 United States Cervical Cancer Pap Smear Test Population & Forecast
14.1.2 United States Cervical Cancer HPV DNA Test Population & Forecast
14.2 United States Cervical Cancer Mortality
14.3 United States Cervical Cancer Test (Screening) Market
14.3.1 United States Cervical Cancer Test Market & Forecast
14.3.2 United States Pap smear Test Market & Forecast
14.3.3 United States HPV DNA Test Market & Forecast

15. Canada – Cervical Cancer Test Analysis
15.1 Canada Cervical Cancer Test (Screening) Population
15.1.1 Canada Cervical Cancer Pap Smear Test Population & Forecast
15.1.2 Canada Cervical Cancer HPV DNA Test Population & Forecast
15.2 Canada Cervical Cancer Mortality
15.3 Canada Cervical Cancer Test (Screening) Market
15.3.1 Canada Cervical Cancer Test Market & Forecast
15.3.2 Canada Pap Smear Test Market & Forecast
15.3.3 Canada HPV DNA Test Market & Forecast

16. Japan – Cervical Cancer Test Analysis
16.1 Japan Cervical Cancer Test (Screening) Population
16.1.1 Japan Cervical Cancer Pap Smear Test Population & Forecast
16.1.2 Japan Cervical Cancer HPV DNA Test Population & Forecast
16.2 Japan Cervical Cancer Mortality
16.3 Japan Cervical Cancer Test (Screening) Market
16.3.1 Japan Cervical Cancer Test Market & Forecast
16.3.2 Japan Pap Smear Test Market & Forecast
16.3.3 Japan HPV DNA Test Market & Forecast

17. South Korea – Cervical Cancer Tests Analysis
17.1 South Korea - Cervical Cancer Test (Screening) Population
17.1.1 South Korea - Cervical Cancer Pap Smear Test Population & Forecast
17.1.2 Korea Cervical Cancer HPV DNA Test Population & Forecast
17.2 Korea Cervical Cancer Mortality
17.3 Korea Cervical Cancer Test (Screening) Market
17.3.1 Korea Cervical Cancer Test Market & Forecast
17.3.2 Korea Pap Smear Test Market & Forecast
17.3.3 Korea HPV DNA Test Market & Forecast

18. Singapore – Cervical Cancer Tests Analysis
18.1 Singapore - Cervical Cancer Test (Screening) Population
18.1.1 Singapore - Cervical Cancer Pap Smear Test Population & Forecast
18.1.2 Singapore Cervical Cancer HPV DNA Test Population & Forecast
18.2 Singapore Cervical Cancer Test (Screening) Market
18.2.1 Singapore Cervical Cancer Test Market & Forecast
18.2.2 Singapore Pap Smear Test Market & Forecast
18.2.3 Singapore HPV DNA Test Market & Forecast

19. Malaysia – Cervical Cancer Test Analysis
19.1 Malaysia - Cervical Cancer Test (Screening) Population
19.1.1 Malaysia Cervical Cancer Pap Smear Test Population & Forecast
19.1.2 Malaysia Cervical Cancer HPV DNA Test Population & Forecast
19.2 Malaysia Cervical Cancer Test (Screening) Market
19.2.1 Malaysia Cervical Cancer Test Market & Forecast
19.2.2 Malaysia Pap Smear Test Market & Forecast
19.2.3 Malaysia HPV DNA Test Market & Forecast

20. Australia – Cervical Cancer Test Analysis
20.1 Australia - Cervical Cancer Test (Screening) Population
20.1.1 Australia Cervical Cancer Pap Smear Test Population & Forecast
20.1.2 Australia Cervical Cancer HPV DNA Test Population & Forecast
20.2 Australia Cervical Cancer Mortality
20.3 Australia Cervical Cancer Test (Screening) Market
20.3.1 Australia Cervical Cancer Test Market & Forecast
20.3.2 Australia Pap Smear Test Market & Forecast
20.3.3 Australia HPV DNA Test Market & Forecast

21. India – Cervical Cancer Test Analysis
21.1 India - Cervical Cancer Test (Screening) Population
21.1.1 India Cervical Cancer Pap Smear Test Population & Forecast
21.1.2 India Cervical Cancer HPV DNA Test Population & Forecast
21.1.3 India Cervical Cancer VIA Test Population & Forecast
21.2 India Cervical Cancer Test (Screening) Market
21.2.1 India Cervical Cancer Test Market & Forecast
21.2.2 India Pap Smear Test Market & Forecast
21.2.3 India HPV DNA Test Market & Forecast
21.2.4 India VIA Test Market & Forecast
22. China – Cervical Cancer Test Analysis
22.1 China - Cervical Cancer Test (Screening) Population
22.1.1 China Cervical Cancer Pap smear Test Population & Forecast
22.1.2 China Cervical Cancer HPV DNA Test Population & Forecast
22.1.3 China Cervical Cancer VIA Test Population & Forecast
22.2 China - Cervical Cancer Test (Screening) Market
22.2.1 China Cervical Cancer Test Market & Forecast
22.2.2 China Pap Smear Test Market & Forecast
22.2.3 China HPV DNA Test Market & Forecast
22.2.4 China VIA Test Market & Forecast

23. Thailand – Cervical Cancer Test Analysis
23.1 Thailand - Cervical Cancer Test (Screening) Population
23.1.1 Thailand Cervical Cancer Pap Smear Test Population & Forecast
23.1.2 Thailand Cervical Cancer VIA Test Population & Forecast
23.2 Thailand Cervical Cancer Test (Screening) Market
23.2.1 Thailand Cervical Cancer Test Market & Forecast
23.2.2 Thailand Pap smear Test Market & Forecast
23.2.3 Thailand VIA Test Market & Forecast

24. Indonesia – Cervical Cancer Test Analysis
24.1 Indonesia Cervical Cancer Test (Screening) Population
24.1.1 Indonesia Cervical Cancer Pap Smear Test Population & Forecast
24.1.2 Indonesia Cervical Cancer HPV DNA Test Population & Forecast
24.1.3 Indonesia Cervical Cancer VIA Test Population & Forecast
24.1.4 Indonesia Cervical Cancer Both (Pap Smear & VIA) Test Population & Forecast
24.2 Indonesia Cervical Cancer Test (Screening) Market
24.2.1 Indonesia Cervical Cancer Test Market & Forecast
24.2.2 Indonesia Pap smear Test Market & Forecast
24.2.3 Indonesia HPV DNA Test Market & Forecast
24.2.4 Indonesia VIA Test Market & Forecast
24.2.5 Indonesia Cervical Cancer Both (Pap Smear & VIA) Test Market & Forecast

25. Cervical Cancer Test Market Growth Drivers
25.1 Point No. 1
25.2 Point No. 2
25.3 Point No. 3

26. Challenges in Cervical Cancer Test Market
26.1 Point No. 1
26.2 Point No. 2

List of Tables

Table 4 1: Worldwide – Cervical Cancer Test Population Share (Percent), 2005 – 2013
Table 4 2: Worldwide – Forecast for Cervical Cancer Test Population Share (Percent), 2014 – 2020
Table 4 3: Worldwide – Cervical Cancer Test Market Share (Percent), 2005 – 2013
Table 4 4: Worldwide – Forecast for Cervical Cancer Test Market Share (Percent), 2014 – 2020
Table 4 5: Worldwide – Cervical Cancer Pap Smear Test Market Share (Percent), 2005 – 2013
Table 4 6: Worldwide – Forecast for Cervical Cancer Pap Smear Test Market Share (Percent), 2014 – 2020
Table 4 7: Worldwide – Cervical Cancer HPV DNA Test Market Share (Percent), 2005 – 2013
Table 4 8: Worldwide – Forecast for Cervical Cancer HPV DNA Test Market Share (Percent), 2014 – 2020
Table 4 9: Worldwide – Cervical Cancer VIA Test Market Share (Percent), 2005 – 2013
Table 4 10: Worldwide – Forecast for Cervical Cancer VIA Test Market Share (Percent), 2014 – 2020
Table 25 1: Worldwide – List of Countries which offer VIA Test via National Programs, 2010
Table 25 2: Worldwide – List of Countries which offer VIA Test via Pilot Programs, 2010
Table 25 3: Worldwide – Prevalence (Percent) of Young Women (15–44 Years) who Have Sex before the Age of 15 Years, 1994 – 2006
Table 25 4: Worldwide – HPV Prevalence (Percent) among Women with Normal Cervical Cytology, 2010

List of Figures

Figure 2 1: Worldwide – Cervical Cancer Test Population (Million), 2005 – 2013
Figure 2 2: Worldwide – Forecast for Cervical Cancer Test Population (Million), 2014 – 2020
Figure 3 1: Worldwide – Cervical Cancer Test Market (Million US$), 2005 – 2013
Figure 3 2: Worldwide – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
Figure 3 3: Worldwide – Cervical Cancer Pap Smear Test Market (Million US$), 2005 – 2013
Figure 3 4: Worldwide – Forecast for Cervical Cancer Pap Smear Test Market (Million US$), 2014 – 2020
Figure 3 5: Worldwide – Cervical Cancer HPV DNA Test Market (Million US$), 2005 – 2013
Figure 3 6: Worldwide – Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2014 – 2020
Figure 3 7: Worldwide – Cervical Cancer VIA Test Market (Million US$), 2005 – 2013
Figure 3 8: Worldwide – Forecast for Cervical Cancer VIA Test Market (Million US$), 2014 – 2020
Figure 5 1: United Kingdom – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
Figure 5 2: United Kingdom – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
Figure 5 3: United Kingdom – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
Figure 5 4: United Kingdom – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
Figure 5 5: United Kingdom – Cervical Cancer Mortality (Number), 2001 – 2011
Figure 5 6: United Kingdom – Cervical Cancer Test Market (Million US$), 2005 – 2013
Figure 5 7: United Kingdom – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
Figure 5 8: United Kingdom – Pap Smear Test Market (Million US$), 2005 – 2013
Figure 5 9: United Kingdom – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
Figure 5 10: United Kingdom – HPV DNA Test Market (Million US$), 2005 – 2013
Figure 5 11: United Kingdom – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020
Figure 6 1: France – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
Figure 6 2: France – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
Figure 6 3: France – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
Figure 6 4: France – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
Figure 6 5: France – Cervical Cancer Mortality (Number), 2001 – 2011
Figure 6 6: France – Cervical Cancer Test Market (Million US$), 2005 – 2013
Figure 6 7: France – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
Figure 6 8: France – Pap Smear Test Market (Million US$), 2005 – 2013
Figure 6 9: France – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
Figure 6 10: France – HPV DNA Test Market (Million US$), 2005 – 2013
Figure 6 11: France – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020
Figure 7 1: Germany – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
Figure 7 2: Germany – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
Figure 7 3: Germany – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
Figure 7 4: Germany – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
Figure 7 5: Germany – Cervical Cancer Mortality (Number), 2001 – 2011
Figure 7 6: Germany – Cervical Cancer Test Market (Million US$), 2005 – 2013
Figure 7 7: Germany – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
Figure 7 8: Germany – Pap Smear Test Market (Million US$), 2005 – 2013
Figure 7 9: Germany – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
Figure 7 10: Germany – HPV DNA Test Market (Million US$), 2005 – 2013
Figure 7 11: Germany – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020
Figure 8 1: Italy – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
Figure 8 2: Italy – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
Figure 8 3: Italy – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
Figure 8 4: Italy – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
Figure 8 5: Italy – Cervical Cancer Mortality (Number), 2001 – 2011
Figure 8 6: Italy – Cervical Cancer Test Market (Million US$), 2005 – 2013
Figure 8 7: Italy – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
Figure 8 8: Italy – Pap Smear Test Market (Million US$), 2005 – 2013
Figure 8 9: Italy – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
Figure 8 10: Italy – HPV DNA Test Market (Million US$), 2005 – 2013
Figure 8 11: Italy – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020
Figure 9 1: Spain – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
Figure 9 2: Spain – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
Figure 9 3: Spain – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
Figure 9 4: Spain – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 –2020
Figure 9 5: Spain – Cervical Cancer Mortality (Number), 2001 – 2011
Figure 9 6: Spain – Cervical Cancer Test Market (Million US$), 2005 – 2013
Figure 9 7: Spain – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
Figure 9 8: Spain – Pap Smear Test Market (Million US$), 2005 – 2013
Figure 9 9: Spain – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
Figure 9 10: Spain – HPV DNA Test Market (Million US$), 2005 – 2013
Figure 9 11: Spain – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020
Figure 10 1: Sweden – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
Figure 10 2: Sweden – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
Figure 10 3: Sweden – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
Figure 10 4: Sweden – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
Figure 10 5: Sweden – Cervical Cancer Mortality (Number), 2001 – 2011
Figure 10 6: Sweden – Cervical Cancer Test Market (Million US$), 2005 – 2013
Figure 10 7: Sweden – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
Figure 10 8: Sweden – Pap Smear Test Market (Million US$), 2005 – 2013
Figure 10 9: Sweden – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
Figure 10 10: Sweden – HPV DNA Test Market (Million US$), 2005 – 2013
Figure 10 11: Sweden – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020
Figure 11 1: Switzerland – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
Figure 11 2: Switzerland – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
Figure 11 3: Switzerland – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
Figure 11 4: Switzerland – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
Figure 11 5: Switzerland – Cervical Cancer Mortality (Number), 2001 – 2011
Figure 11 6: Switzerland – Cervical Cancer Test Market (Million US$), 2005 – 2013
Figure 11 7: Switzerland – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
Figure 11 8: Switzerland – Pap Smear Test Market (Million US$), 2005 – 2013
Figure 11 9: Switzerland – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
Figure 11 10: Switzerland – HPV DNA Test Market (Million US$), 2005 – 2013
Figure 11 11: Switzerland – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020
Figure 12 1: Norway – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
Figure 12 2: Norway – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
Figure 12 3: Norway – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
Figure 12 4: Norway – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
Figure 12 5: Norway – Cervical Cancer Mortality (Number), 2001 – 2011
Figure 12 6: Norway – Cervical Cancer Test Market (Million US$), 2005 – 2013
Figure 12 7: Norway – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
Figure 12 8: Norway – Pap Smear Test Market (Million US$), 2005 – 2013
Figure 12 9: Norway – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
Figure 12 10: Norway – HPV DNA Test Market (Million US$), 2005 – 2013
Figure 12 11: Norway – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020
Figure 13 1: Netherlands – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
Figure 13 2: Netherlands – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
Figure 13 3: Netherlands – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
Figure 13 4: Netherlands – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
Figure 13 5: Netherlands – Cervical Cancer Mortality (Number), 2001 – 2011
Figure 13 6: Netherlands – Cervical Cancer Test Market (Million US$), 2005 – 2013
Figure 13 7: Netherlands – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
Figure 13 8: Netherlands – Pap Smear Test Market (Million US$), 2005 – 2013
Figure 13 9: Netherlands – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
Figure 13 10: Netherlands – HPV DNA Test Market (Million US$), 2005 – 2013
Figure 13 11: Netherlands – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020
Figure 14 1: United States – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
Figure 14 2: United States – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
Figure 14 3: United States – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
Figure 14 4: United States – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
Figure 14 5: United States – Cervical Cancer Mortality (Number), 2001 – 2011
Figure 14 6: United States – Cervical Cancer Test Market (Million US$), 2005 – 2013
Figure 14 7: United States – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
Figure 14 8: United States – Pap smear Test Market (Million US$), 2005 – 2013
Figure 14 9: United States – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
Figure 14 10: United States – HPV DNA Test Market (Million US$), 2005 – 2013
Figure 14 11: United States – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020
Figure 15 1: Canada – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
Figure 15 2: Canada – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
Figure 15 3: Canada – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
Figure 15 4: Canada – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
Figure 15 5: Canada – Cervical Cancer Mortality (Number), 2001 – 2011
Figure 15 6: Canada – Cervical Cancer Test Market (Million US$), 2005 – 2013
Figure 15 7: Canada – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
Figure 15 8: Canada – Pap Smear Test Market (Million US$), 2005 – 2013
Figure 15 9: Canada – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
Figure 15 10: Canada – HPV DNA Test Market (Million US$), 2005 – 2013
Figure 15 11: Canada – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020
Figure 16 1: Japan – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
Figure 16 2: Japan – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
Figure 16 3: Japan – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
Figure 16 4: Japan – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
Figure 16 5: Japan – Cervical Cancer Mortality (Number), 2001 – 2011
Figure 16 6: Japan – Cervical Cancer Test Market (Million US$), 2005 – 2013
Figure 16 7: Japan – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
Figure 16 8: Japan – Pap Smear Test Market (Million US$), 2005 – 2013
Figure 16 9: Japan – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
Figure 16 10: Japan – HPV DNA Test Market (Million US$), 2005 – 2013
Figure 16 11: Japan – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020
Figure 17 1: Korea – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
Figure 17 2: Korea – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
Figure 17 3: Korea – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
Figure 17 4: Korea – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
Figure 17 5: Korea – Cervical Cancer Mortality (Number), 2001 – 2011
Figure 17 6: Korea – Cervical Cancer Test Market (Million US$), 2005 – 2013
Figure 17 7: Korea – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
Figure 17 8: Korea – Pap Smear Test Market (Million US$), 2005 – 2013
Figure 17 9: Korea – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
Figure 17 10: Korea – HPV DNA Test Market (Million US$), 2005 – 2013
Figure 17 11: Korea – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020
Figure 18 1: Singapore – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
Figure 18 2: Singapore – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
Figure 18 3: Singapore – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
Figure 18 4: Singapore – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
Figure 18 5: Singapore – Cervical Cancer Test Market (Million US$), 2005 – 2013
Figure 18 6: Singapore – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
Figure 18 7: Singapore – Pap Smear Test Market (Million US$), 2005 – 2013
Figure 18 8: Singapore – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
Figure 18 9: Singapore – HPV DNA Test Market (Million US$), 2005 – 2013
Figure 18 10: Singapore – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020
Figure 19 1: Malaysia – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
Figure 19 2: Malaysia – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
Figure 19 3: Malaysia – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
Figure 19 4: Malaysia – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
Figure 19 5: Malaysia – Cervical Cancer Test Market (Million US$), 2005 – 2013
Figure 19 6: Malaysia – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
Figure 19 7: Malaysia – Pap smear Test Market (Million US$), 2005 – 2013
Figure 19 8: Malaysia – Forecast for Pap smear Test Market (Million US$), 2014 – 2020
Figure 19 9: Malaysia – HPV DNA Test Market (Million US$), 2005 – 2013
Figure 19 10: Malaysia – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020
Figure 20 1: Australia – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
Figure 20 2: Australia – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
Figure 20 3: Australia – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
Figure 20 4: Australia – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
Figure 20 5: Australia – Cervical Cancer Mortality (Number), 2001 – 2011
Figure 20 6: Australia – Cervical Cancer Test Market (Million US$), 2005 – 2013
Figure 20 7: Australia – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
Figure 20 8: Australia – Pap Smear Test Market (Million US$), 2005 – 2013
Figure 20 9: Australia – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
Figure 20 10: Australia – HPV DNA Test Market (Million US$), 2005 – 2013
Figure 20 11: Australia – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020
Figure 21 1: India – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
Figure 21 2: India – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
Figure 21 3: India – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
Figure 21 4: India – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
Figure 21 5: India – Cervical Cancer VIA Test Population (Thousand), 2005 – 2013
Figure 21 6: India – Forecast for Cervical Cancer VIA Test Population (Thousand), 2014 – 2020
Figure 21 7: India – Cervical Cancer Test Market (Million US$), 2005 – 2013
Figure 21 8: India – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
Figure 21 9: India – Pap smear Test Market (Million US$), 2005 – 2013
Figure 21 10: India – Forecast for Pap smear Test Market (Million US$), 2014 – 2020
Figure 21 11: India – HPV DNA Test Market (Million US$), 2005 – 2013
Figure 21 12: India – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020
Figure 21 13: India – VIA Test Market (Million US$), 2005 – 2013
Figure 21 14: India – Forecast for VIA Test Market (Million US$), 2014 – 2020
Figure 22 1: China – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
Figure 22 2: China – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
Figure 22 3: China – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
Figure 22 4: China – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
Figure 22 5: China – Cervical Cancer VIA Test Population (Thousand), 2005 – 2013
Figure 22 6: China – Forecast for Cervical Cancer VIA Test Population (Thousand), 2014 – 2020
Figure 22 7: China – Cervical Cancer Test Market (Million US$), 2005 – 2013
Figure 22 8: China – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
Figure 22 9: China – Pap smear Test Market (Million US$), 2005 – 2013
Figure 22 10: China – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
Figure 22 11: China – HPV DNA Test Market (Million US$), 2005 – 2013
Figure 22 12: China – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020
Figure 22 13: China – VIA Test Market (Million US$), 2005 – 2013
Figure 22 14: China – Forecast for VIA Test Market (Million US$), 2014 – 2020
Figure 23 1: Thailand – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
Figure 23 2: Thailand – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
Figure 23 3: Thailand – Cervical Cancer VIA Test Population (Thousand), 2005 – 2013
Figure 23 4: Thailand – Forecast for Cervical Cancer VIA Test Population (Thousand), 2014 – 2020
Figure 23 5: Thailand – Cervical Cancer Test Market (Million US$), 2005 – 2013
Figure 23 6: Thailand – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
Figure 23 7: Thailand – Pap smear Test Market (Million US$), 2005 – 2013
Figure 23 8: Thailand – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
Figure 23 9: Thailand – VIA Test Market (Million US$), 2005 – 2013
Figure 23 10: Thailand – Forecast for VIA Test Market (Million US$), 2014 – 2020
Figure 24 1: Indonesia – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
Figure 24 2: Indonesia – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
Figure 24 3: Indonesia – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
Figure 24 4: Indonesia – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
Figure 24 5: Indonesia – Cervical Cancer VIA Test Population (Thousand), 2005 – 2013
Figure 24 6: Indonesia – Forecast for Cervical Cancer VIA Test Population (Thousand), 2014 – 2020
Figure 24 7: Indonesia – Cervical Cancer Both (Pap Smear & VIA) Test Population (Thousand), 2005 – 2013
Figure 24 8: Indonesia – Forecast for Cervical Cancer Both (Pap Smear & VIA) Test Population (Thousand), 2014 – 2020
Figure 24 9: Indonesia – Cervical Cancer Test Market (Million US$), 2005 – 2013
Figure 24 10: Indonesia – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
Figure 24 11: Indonesia – Pap Smear Test Market (Million US$), 2005 – 2013
Figure 24 12: Indonesia – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
Figure 24 13: Indonesia – HPV DNA Test Market (Million US$), 2005 – 2013
Figure 24 14: Indonesia – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020
Figure 24 15: Indonesia – VIA Test Market (Million US$), 2005 – 2013
Figure 24 16: Indonesia – Forecast for VIA Test Market (Million US$), 2014 – 2020
Figure 24 17: Indonesia – Both (Pap smear & VIA) Test Market (Million US$), 2005 – 2013
Figure 24 18: Indonesia – Forecast for Both (Pap Smear & VIA) Test Market (Million US$), 2014 – 2020

Related Reports

PharmaPoint: Prophylactic Human Papillomavirus Vaccines – Japan Drug Forecast and Market Analysis to 2022The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift […]
2014-2018 Spanish Molecular Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies–Infectious Diseases, Genetic Diseases, Cancer, Forensic and Paternity TestingThis report presents a comprehensive analysis of the Spanish molecular diagnostics market, including: Major issues pertaining to the Spanish molecular diagnostics laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. An extensive review of DNA probe and biochip technologies, test formats, detection methodologies, trends in testing automation and amplification […]
2014-2018 French Molecular Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies–Infectious Diseases, Genetic Diseases, Cancer, Forensic and Paternity TestingThis report presents a comprehensive analysis of the French molecular diagnostics market, including: Major issues pertaining to the French molecular diagnostics laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. An extensive review of DNA probe and biochip technologies, test formats, detection methodologies, trends in testing automation and amplification […]
Global Cervical Cancer Diagnostic Tests Market 2014-2018Cervical cancer diagnostic tests are used to identify the presence of the precancerous or cancerous lesions in the cervix of a woman. These tests include an initial screening using pap smear and HPV testing, and upon positive results, colposcopy and biopsy are further utilized to confirm the diagnosis. After the positive diagnosis, the patient is further subjected to imaging tests that are used to establish the grade of cancer. TechNavio's analysts forecast the Global Cervical […]
Future Horizons and Growth Strategies in the Beta-2 Microglobulin Testing Market 2014: Supplier Shares and Country ForecastsThe cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic […]